Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of DTaP-IPV-Hep B-PRP-T vaccine in Indian infants after hepatitis B birth dose
2016-002089-29Phase 3
- Sponsor
- Sanofi
- Start
- May 2016
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of DTaP-IPV-Hep B-PRP-T vaccine in diphtheria, Tetanus, pertussis and 3 more, sponsored by Sanofi. Primary endpoint: Seroprotection and vaccine response one month after third dose.
02
Drugs
DTaP-IPV-Hep B-PRP-T vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2016-002089-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002089-29.